CoChat

Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)

Open access
Zhang, Fugui, Li, Yong, Zhang, Hongmei, Huang, Enyi, Gao, Lina, Luo, Wenping, Wei, Qiang, Fan, Jiaming, Song, Dongzhe, Liao, Junyi, Zou, Yulong, Liu, Feng, Liu, Jianxiang, Huang, Jiayi, Guo, Dan, Ma, Chao, Hu, Xue, Li, Li, Qu, Xiangyang, Chen, Liqun, Yu, Xinyi, Zhang, Zhicai, Wu, Tingting, Luu, Hue H., Haydon, Rex C., Song, Jinlin, He, Tong-Chuan, Ji, Ping · 2017 · Oncotarget
Cited by 65

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Fugui Zhang 1, 2 , Yong Li 1 , Hongmei Zhang 1, 2 , Enyi Huang 1, 2 , Lina Gao 1 , Wenping Luo 1, 2 , Qiang Wei 2, 3 , Jiaming Fan 2, 3 , Dongzhe Song 2, 4 , Junyi Liao 2, 3 , Yulong Zou 2, 3 , Feng Liu 2, 3 , Jianxiang Liu 2, 5 , Jiayi Huang 2, 3 , Dan Guo 2, 3 , Chao Ma 2, 6 , Xue Hu 2, 3 , Li Li 2, 7 , Xiangyang Qu 2, 3 , Liqun Chen 2, 3 , Xinyi Yu 2, 3 , Zhicai Zhang 2, 5 , Tingting Wu 2, 8 , Hue H. Luu 2 , Rex C. Haydon 2 , Jinlin Song 1 , Tong-Chuan He 1, 2, 3 , Ping Ji 1 1 Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, and the Affiliated Hospital of Stomatology of Chongqing Medical University, Chongqing, China 2 Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, USA 3 Ministry of Education Key Laboratory of Diagnostic Medicine, and the Affiliated Hospitals of Chongqing Medical University, Chongqing, China 4 Department of Conservative Dentistry and Endodontics, West China Hospital and West China School of Stomatology, Sichuan University, Chengdu, China 5 Department of Orthopaedic Surgery, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 6 Department of General Surgery, The Affiliated Zhongnan Hospital of Wuhan University, Wuhan, China 7 Department of Biomedical Engineering, School of Bioengineering, Chongqing University, Chongqing, China 8 Department of Neurosurgery, The Affiliated Zhongnan Hospital of Wuhan University, Wuhan, China Correspondence to: Tong-Chuan He, email: tche@uchicago.edu Ping Ji, email: jiping-62@hotmail.com Keywords: head and neck squamous cell carcinoma, mebendazole, drug repurposing, keratinization, differentiation therapy Received: October 17, 2016 Accepted: January 09, 2017 Published: January 16, 2017 ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is one of the most common and aggressive types of human cancers worldwide. Nearly a half of HNSCC patients experience recurrence within five years of treatment and develop resistance to chemotherapy. Thus, there is an urgent clinical need to develop safe and novel anticancer therapies for HNSCC. Here, we investigate the possibility of repurposing the anthelmintic drug mebendazole (MBZ) as an anti-HNSCC agent. Using the two commonly-used human HNSCC lines CAL27 and SCC15, we demonstrate MBZ exerts more potent anti-proliferation activity than cisplatin in human HNSCC cells. MBZ effectively inhibits cell proliferation, cell cycle progression and cell migration, and induces apoptosis of HNSCC cells. Mechanistically, MBZ can modulate the cancer-associated pathways including ELK1/SRF, AP1, STAT1/2, MYC/MAX, although the regulatory outcomes are context-dependent. MBZ also synergizes with cisplatin in suppressing cell proliferation and inducing apoptosis of human HNSCC cells. Furthermore, MBZ is shown to promote the terminal differentiation of CAL27 cells and keratinization of CAL27-derived xenograft tumors. Our results are the first to demonstrate that MBZ may exert its anticancer activity by inhibiting proliferation while promoting differentiation of certain HNSCC cancer cells. It’s conceivable the anthelmintic drug MBZ can be repurposed as a safe and effective agent used in combination with other frontline chemotherapy drugs such as cisplatin in HNSCC treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.14673

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 65

Metadata

Authors
Zhang, F., Li, Y., Zhang, H., Huang, E., Gao, L., Luo, W., Wei, Q., Fan, J., Song, D., Liao, J., Zou, Y., Liu, F., Liu, J., Huang, J., Guo, D., Ma, C., Hu, X., Li, L., Qu, X., Chen, L., Yu, X., Zhang, Z., Wu, T., Luu, H. H., Haydon, R. C., Song, J., He, T.-C., & Ji, P.
Venue
Oncotarget
Published
2017-01-16
Volume
8
Issue
8
Pages
12968-12982
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2573710850
Cited by
65
References
5
FWCI
7.70
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC). https://app.cochat.ai/papers/10.18632/oncotarget.14673
The paper
Zhang, F., Li, Y., Zhang, H., Huang, E., Gao, L., Luo, W., Wei, Q., Fan, J., Song, D., Liao, J., Zou, Y., Liu, F., Liu, J., Huang, J., Guo, D., Ma, C., Hu, X., Li, L., Qu, X., . . . Ji, P. (2017). Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC). Oncotarget. https://doi.org/10.18632/oncotarget.14673

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.